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Background: Low birth weight has been linked to an increased risk to develop obesity, type 2 diabetes, and
hypertension in adult life, although the mechanisms underlying the association are not well understood. The
objective was to determine whether the metabolomic profile of plasma from umbilical cord differs between low
and normal birth weight newborns.
Methods: Fifty healthy pregnant women and their infants were selected. The eligibility criteria were being born at
term and having a normal pregnancy. Pairs were grouped according to their birth weight: low birth weight (LBW,
birth weight < 10th percentile, n = 20) and control (control, birth weight between the 75th-90th percentiles, n = 30).
Nuclear Magnetic Resonance (NMR) was used to generate metabolic fingerprints of umbilical cord plasma samples.
Simultaneously, the metabolomic profiles of the mothers were analysed. The resulting data were subjected to
chemometric, principal component and partial least squares discriminant analyses.
Results: Umbilical cord plasma from LBW and control newborns displayed a clearly differentiated metabolic profile.
Seven metabolites were identified that discriminate the LBW from the control group. LBW newborns had lower
levels of choline, proline, glutamine, alanine and glucose than did the control newborns, while plasma levels of
phenylalanine and citrulline were higher in LBW newborns (p < 0.05). No significant differences were found
between the two groups of mothers.
Conclusions: Low birth weight newborns display a differential metabolomic profile than those of normal birth
weight, a finding not present in the mothers. The meaning and the potential utility of the findings as biomarkers of
risk need to be addressed in future studies.
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The concept of the fetal origin of adult disease suggests
that early life conditions can “program” the fetus for a
spectrum of adverse health outcomes in adulthood [1,2].
Low birth weight babies (LBW), typically defined as
birth weight below the 10th percentile according to ges-
tational age [3], have an increased risk of rapid postnatal
weight gain, later obesity, and diseases in adulthood such
as type 2 diabetes, hypertension and ischemic heart dis-
ease [4-6]. Therefore, cardiovascular risk is determined* Correspondence: empar.lurbe@uv.es
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reproduction in any medium, provided the ornot only by conventional risk factors of importance in
adult life, but also by early life programming based on
intrauterine fetal growth [7].
The mechanistic pathways underlying the relationship
between fetal growth restriction and cardiovascular risk
are poorly understood [8]. Although the cause of this re-
lationship is unknown, several hypotheses have been
proposed: involvement of the kidney (reduction of neph-
ron number, activation of the renin-angiotensin system,
an increase in renal sympathetic nerve activity), the neu-
roendocrine system (up-regulation of the hypothalamic-
pituitary-adrenal axis, altered adaptation to stress), and
early abnormalities in the vasculature tree [9,10].
A previous study has demonstrated that endothelial
cells from umbilical cord artery derived from individualsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that from individuals of higher birth weight [11]. This
observation could imply that it is possible to identify
functional and/or structural differences at birth which
can contribute to providing better information with re-
spect to the risk of developing disease later in life. A fur-
ther approach to studying differences between low and
normal birth weight newborns is to assess their metabo-
lomic profiles.
Metabolomics, the study of small-molecule metabo-
lites, is a discipline that focuses on the measurement of
the relative concentrations of endogenous small mole-
cules in biofluids. This technology may be useful for
understanding metabolic imbalances and for diagnosing
human diseases. Recently, studies using metabolomics
have been used to identify a discriminatory metabolite
profile in a number of areas: preeclampsia in early preg-
nancy [12], diabetes [13], obesity [14], [15], risk for pre-
term delivery [16]. It has been suggested they predict the
presence and severity of cardiovascular disease [17-20].
There are no data about its use to identify a metabolite
profile in umbilical cord from LBW children. The ob-
jective of the present study was to analyse the metabolo-
mic profile at birth in newborns with LBW, and to
compare it with those from normal birth weight chil-
dren. Simultaneously, the metabolomic profiles of their
mothers were analysed. The identification of deregulated
metabolites would potentially give clues for better
understanding the abnormalities associated with LBW.
Methods
Subjects and sample collection
Newborns were included if born at term (gestational age
≥37 weeks), after uncomplicated pregnancies ascertained
according to the Ballard method [21], and by normal de-
livery or Cesarean section in the absence of perinatal ill-
ness at the Hospital General Universitario of Valencia,
Spain. All the mothers were healthy and had no cardio-
vascular risk factors. Fifty newborns and their mothers
of European origin were selected to participate in the
study. Umbilical cord blood samples were obtained from
the clamped umbilical cord immediately after delivery.
The samples of their mothers were drawn at 2–4 h after
delivery in non-fasting conditions, but with at least 8
hours having passed since the last meal and blood sam-
pling. Two groups of newborns were created according
to birth weight: lower than the 10th percentile (lower
than 2.5 kg; LBW group, n = 20) or appropriate birth
weight for gestational age (control group, birth weight
between the 75th-90th percentiles, n = 30) [22]. Parents
gave their consent for the study after they were given
informed in writing of the objectives of the research pro-
ject and of the samples that would be taken. The study
was approved by the hospital’s review board and wascarried out in accordance with the Declaration of Hel-
sinki. Both the samples (plasma from umbilical cord of
the newborns and plasma from peripheral veins from
the mothers), as well as the collected data, were stored
according to the directives dictated by the law of Bio-
medical Investigation of 2007 (Law 14/2007) and all ap-
plicable rules.
Metabolomic profile
Storage, preparation and 1 H Nuclear magnetic resonance
spectroscopic analysis of blood plasma
Umbilical venous cord blood and maternal peripheral
venous blood were collected in EDTA-tubes, centrifuged
to yield plasma, stored at −80 °C and thawed before use.
For Nuclear Magnetic Resonance (NMR) analysis, 500 μl
of plasma were mixed with 50 μl of D2O (as a field lock).
A total of 500 μl of the mixture of each sample was then
individually transferred into a 5 mm high quality NMR
tube. All 1 H NMR spectra were acquired using a stand-
ard one-dimensional pulse sequence with water suppres-
sion (Bruker Avance 600 spectrometer operating at
600.13 MHz with a 1 mm 1 H/13 C/15 N TXI probe). A
total of 256 FIDs (free induction decay) were collected
into 64 k data points with a spectral width of 14 ppm
and a recycle delay (RD) of 1 s. The water signal was
saturated with weak irradiation during the recycle delay.
Before Fourier transformation, the free induction decay
was multiplied by a 0.3 Hz exponential line broadening.
Spectral chemical shift referencing on the Alanine
CH3 doublet signal at 1.475 ppm was performed in all
spectra. Resonances in these spectral regions were
assigned using the literature [23] and two-dimensional
spectra were selected (2D NMR, especially for long
chain metabolites). Spectral regions between 0.5 and 4.5
ppm and between 5.5 and 9.5 ppm were binned in seg-
ments of 0.01 ppm width (6 Hz) for multivariate ana-
lysis. Data binning in NMR spectra for multivariate
analysis is a common pre-processing practice [24,25],
which, although it may decrease the effect of minor
observations, allows for the detection of relevant
regions, decreases the risk of model overfitting and arti-
ficially increases the signal to noise-ratio. Data binning
reduces the impact of read noise on the processed data
at the cost of a lower resolution. We used binning only
for the pattern recognition. There are two benefits asso-
ciated with the use of pattern recognition approaches in
the binning of spectral data. First, the signal-to-noise
ratio increases. Second, there is a reduction in the possi-
bility of overfitting. Once the bucket with the relevant
peaks in each spectra were identified, they were quanti-
fied. Therefore, the values reported are quantified peaks
by spectral integration. The binned data was normalised
to the total spectral area. Thus, the individual peak in-
tensities were normalized to total metabolite content for
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belonging to the EDTA resonances (2.52 to 2.57 ppm
and 3.06 to3.17 ppm) were removed from the spectra for
subsequent analysis. The available spectral databases and
2D NMR experiments were used to aid in structural
identification of the relevant metabolites. All spectra
were processed using Topspin 1.3 (Bruker Biospin
GmbH, Germany) and transferred to MATLABW (Math-
Works Inc, 2006) using in-house scripts for data ana-
lysis. Signals belonging to selected metabolites were
integrated and quantified using semi-automated in-
house MATLAB peak-fitting routines. These fitting rou-
tines were based on Levenburg-Marquard optimization
procedures. The target function for the optimization
included experimental spectra measured for standard
solutions of selected metabolites with complex multiplet
patterns and theoretically generated Lorentzian-shape
signals for those metabolites with simpler spectral pat-
terns. One way analysis of variance (ANOVA) was used
for the determination of statistical significance between
group means of the corresponding integrals.
Multivariate analysis of nuclear magnetic resonance
spectra
In the present study, binned spectral regions for blood
plasma were mean-centered chemometric analyses. Rele-
vant bins were identified in our chemometric models.
The relevant spectral regions within these bins were
identified and quantified by spectral integration. Chemo-
metric and statistical analyses were performed using in-
house MATLAB scripts and the PLS Toolbox (Eigen-
vector Research, Inc.). Principal Component Analysis
(PCA) and Projection to Latent Structures for Discrim-
inant Analysis (PLS-DA) were applied to NMR spectra
data sets. PCA is able to find low dimensional embed-
dings of multivariate data in a way that optimally pre-
serves the structure of the data. The PCA technique
transforms the variables of a data set into a smaller
number of new latent variables called principal compo-
nents (PCs) which are uncorrelated to each other and
account for decreasing proportions of the total variance
of the original variables. Each new PC is a linear com-
bination of the original variation so that a compact de-
scription of the variation within the data set is
generated. Observations are assigned scores according to
the variation measured by the principal component X,
with those having similar scores clustering together.
Where PCA proved inadequate to define clustering, a
supervised approach was used.
PLS-DA is a classification technique that combines the
properties of Partial Least Squares regression with the
discrimination power of discriminant analysis [26]. The
main advantage of PLS-DA models is that the main
sources of variability in the data are modeled by the so-called latent variables (LVs) and, consequently, in their
associated scores and loadings. This allows for the
visualization and understanding of different patterns and
relations in the data. PLS-DA is a supervised extension
of PCA that is used to distinguish two or more classes
by searching for variables (X matrix) that are correlated
to class membership (Y matrix). In this approach, the
axes are calculated to maximize class separation and can
be used to examine separation that would otherwise be
across three or more principal components [26]. In
order to discriminate between samples associated with
low weight and normal weight at birth, a PLS-DA model
was devised. The PLS-DA model discriminating between
controls and LBW was cross-validated by technical repli-
cation of the whole process on 25 random data splits.
To validate the model, important quality parameters
were calculated: R2X, R2Y, Q2 and RMSP. R2X and R2Y
describe the variation in the X and Y variables, respect-
ively. Q2 describes predictability. RMSP (Root mean
squared error of prediction) gives a direct indication of
the error in the predicted value.
Statistical analysis
Values were expressed as mean ± SD for each study
group. The differences in the mean values of anthropo-
metric parameters between the groups were assessed by
analysis of variance (ANOVA) adjusted by sex. The nor-
mality of the data was verified using the Kolmogorov-
Smirnov test. Choline, glutamine, alanine and glycogen
in the control group do not have a normal distribution,
and a Kruskal-Wallis test was used for these variables.
An outlier analysis was performed, and those samples
deviating from the mean by more than 2.5 times the
standard deviation were excluded. A significant differ-
ence was considered present if p < 0.05. Pearson’s cor-
relation coefficients were used to examine the relations
between variables. Statistical analyses were performed
using SPSS 15.0. (SPSS Inc, Chicago, Illinois, USA) and
GraphPad Statmate 5.0 (GraphPad Software, La Jolla,
California, USA) software graphs.
Results
Clinical characteristics of mothers and newborns
The general characteristics of mothers and their new-
borns are shown in Table 1. No differences were
observed in maternal age, maternal BMI, pregnancy
weight gain or type of delivery between the two groups.
Although no significant differences were observed in
heart rate and diastolic blood pressure between new-
borns groups (Table 1), differences appeared in sex,
height, head circumference and blood pressure. As
expected, the LBW group had systolic values signifi-
cantly lower than those for the control birth weight
group [10]. All comparisons between newborns groups
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comparing boys with girls.
Metabolomic profile in umbilical cord blood in low birth
weight and control newborns
The standard 1D NMR spectrum is shown in Figure 1A.
PCA and PLS-DA scatter plot were performed on the
pre-processed NMR spectra comparing plasma from
LBW versus control newborns and were used to identify
metabolite clusters. Although an unsupervised analysis
by PCA does not show differences between groups,
Figure 1B, a supervised classification method (PLS-DA,
3 Latent Variables, see Additional file 1: Figure S1) pro-
vides a differential global metabolic profile, Figure 1C.
The model had a R2X (cumulative) of 0.623, a R2Y (cu-
mulative) of 0.871, a Q2 (cumulative) of 0.523 (a Q2
value superior to 0.5 is generally considered to be a good
predictor) and a RMSP of 0.417 (medium predictive cap-
acity). Spectral regions and peaks with the highest con-
tribution to the loadings plot from this model were
further quantified and analysed. Many metabolites may
contribute to these loading plots and to the separation
between classes. A total of thirty-four metabolites were
tested in fifty-eight spectral regions, and the differences
were evaluated by the T-Student test with the Kruskal-
Wallis correction. However, only those that differed with
p < 0.05 were taken into consideration.
Of the 34 metabolic regions studied, 17 compounds
were quantified according to the loadings of the multi-
variate analysis. Among the 17 metabolites, significant
differences were observed for seven (proline, free cho-
line, glutamine, alanine, glucose, phenylalanine andTable 1 Anthropometric and clinical characteristics of mother
Control (n = 30)
Maternal Characteristics
Maternal age (years) 30.22 ± 5.65
Pregnancy weight gain (g) 12581 ± 428
Delivery (vaginal/Cesarean section) 21/9 (70%)
Maternal Body Mass Index 24.0 ± 3.1
Newborns Characteristics
Gestational age at delivery (weeks) 38.95 ± 0.90
Sex (male/female) 20/10 (66.7%)
Birth weight (g) 3756 ± 148
Height (cm) 50.46 ± 1.45
Head circumference (cm) 34.70 ± 1.00
Systolic blood pressure (mmHg) 73.88 ± 13.20
Diastolic blood pressure (mmHg) 44.20 ± 11.22
Heart rate (bpm) 130.14 ± 16.30
The values are expressed as mean ± SD; p-value, statistical significance of the differcitrulline) between the LBW and the control group,
while no differences were observed in the other seven
(spectral region containing lipoproteins peaks, in carbo-
hydrates and glycogen fragments, in ketone bodies like
acetoacetate and hydroxybutyrate, in total lipids and in
fatty acids both saturated and unsaturated) (data not
shown).
Table 2 shows median values ± SD for arbitrary units
of intensity (AUIx10-3) from identified metabolites, and
Figure 2 provides the individual levels of 7 metabolites
that display significant level differences between the two
groups. In the LBW group, all metabolites have a normal
distribution, and samples are more homogeneous than
in the control group. In the control group, choline, glu-
tamine and alanine do not have a normal distribution.
An outlier analysis was carried out, and two subjects
were excluded from the control group.
Five metabolites (proline, choline, glutamine, alanine
and glucose) were reduced in the LBW group as com-
pared to those for the controls. In the LBW group, pro-
line values were 38.1% less (21.74 ± 9.80 AUI vs 13.00 ±
7.5 AUI; p-value = 0.002) while free choline was 31.4%
less (3.76 ± 0.17 AU vs 2.58 ± 0.07 AU; p-value = 0.005).
Glutamine (3.68 ± 0.17 vs 2.59 ± 0.07; p-value = 0.004),
alanine (9.49 ± 4.1 vs 7.00 ± 2.2; p-value = 0.008) and
glucose levels (2.15 ± 0.98 vs 1.59 ± 0.50; p-value =
0.023) were significantly lower in LBW newborns as
well. In addition, LBW newborns exhibited a 15.7% in-
crease in values of phenylalanine (1.07 ± 0.03 vs 1.27 ±
0.03 p-value = 0.018) and a 20.2% increase in values of
citrulline (0.67 ± 0.02 vs 0.84 ± 0.002; p-value = 0.008).
No difference in profiles between sexes was observed.s and newborns grouped by birth weight
LBW (n = 20) p-value
30.50 ± 6.10 NS
11025 ± 301 NS
12/8 (60%) NS
22.8 ± 2.1 NS
37.64 ± 1.50 p < 0.05
5/15 (33.3%) p < 0.01
2371 ± 177 p < 0.0001
45.55 ± 1.14 p < 0.0001
32.10 ± 1.80 p < 0.0001
65.15 ± 11.50 p < 0.05
40.70 ± 8.70 NS
128.33 ± 17.90 NS
ences among groups; NS, Non-significant; LBW, low birth weight.
Figure 1 Umbilical cord blood profile. Superposed 1 H NMR spectra for the spectra of umbilical cord blood plasma (Panel A), Principal
Component Analysis scores plot (PCA, panel B), and Projection to Latent Structures for Discriminant Analysis scores plot (PLS-DA, panel C)
showing the global metabolic differences between low birth weight (open circles, blue spectra) and control birth weight (black triangles and red
spectra) newborns. Although an unsupervised analysis by PCA does not show differences between groups, a supervised classification method
(PLS-DA) provides a differential global metabolic profile. The cross-validated error percentage of the model for the classification of low weight at
birth samples is 8 %. Metabolites exhibiting largest differences between groups have been listed in Table 2.
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Nuclear Magnetic Resonance data from mothers were
processed to give the initial PCA plot after a partial least
squares-discriminate analysis (Figure 3, PLS-DA, 3 La-
tent Variables, see Additional file 1: Figure S2). The
PLS-DA model had a R2X (cumulative) of 0.512, a R2Y
(cumulative) of 0.611, a Q2 (cumulative) of 0.502 (a Q2
value superior to 0.5 is generally considered to be a good
predictor) and a RMSP of 0.282 (low predictive cap-
acity). The loadings plot showed 14 spectral regions with
high relative weight belonging to 10 metabolites. Table 2
shows median values ± SD for arbitrary units of intensity(AUIx10-3) from the identified metabolites. From a total
of 10 metabolites, 6 were related to the amino acid
group (proline, phenylalanine, alanine, glutamine, citrul-
line and free choline), 2 were related to the carbohydrate
group (glucose and glycogen fragments), and 2 to the
lipid group (spectral region containing large LDL +
VLDL lipoproteins peaks and polyunsaturated fatty acids
(PUFAs)). The results of the metabolomic profiling in
maternal blood showed no significant differences be-
tween the two groups of mothers at either the PLS-DA
score plot level and at the individual identified metabol-
ite level (Table 2, p-value M-C vs M-LBW).
Table 2 List of identified metabolites in umbilical cord plasma and in maternal peripheral blood















Proline 21.74 ± 9.80 13.00 ± 7.50 0.002 12.22 ± 0.92 12.10 ± 0.56 NS 1.73 ± 0.83 1.26 ± 0.62 0.023
Free Choline 3.76 ± 0.17 2.58 ± 0.07 0.005 5.73 ± 0.79 5.80 ± 0.76 NS 0.56 ± 0.17 0.46 ± 0.17 0.040
Citrulline 0.67 ± 0.02 0.84 ± 0.02 0.008 15.16 ± 1.09 15.34 ± 1.22 NS 0.04 ± 0.01 0.05 ± 0.02 0.022
Glutamine 3.68 ± 0.17 2.59 ± 0.07 0.004 0.85 ± 0.06 0.85 ± 0.07 NS 3.68 ± 1.16 3.07 ± 0.81 0.024
Alanine 9.49 ± 4.10 7.00 ± 2.20 0.008 0.90 ± 0.03 0.96 ± 0.20 NS 9.28 ± 3.29 7.66 ± 2.64 0.041
Phenylalanine 1.07 ± 0.03 1.27 ± 0.03 0.018 9.78 ± 1.13 9.97 ± 0.96 NS 0.12 ± 0.03 0.13 ± 0.03 NS
Carbohydrates
Glucose 2.15 ± 0.98 1.59 ± 0.50 0.023 1.12 ± 0.08 1.10 ± 0.09 NS 1.65 ± 0.58 1.43 ± 0.42 NS
Glycogen fragments 2.70 ± 1.11 2.01 ± 0.76 0.011 2.95 ± 0.33 2.82 ± 0.24 NS 0.81 ± 0.24 0.71 ± 0.27 NS
Lipids
LDL + VLDL enriched
spectral region
7.22 ± 1.25 7.60 ± 0.99 NS 5.01 ± 0. 50 4.96 ± 0.52 NS 1.52 ± 0.33 1.55 ± 0.23 NS
PUFA N/D N/D – 4.19 ± 0.49 4.38 ± 0.38 NS – – –
The values are expressed as mean ± SD; p-value, statistical significance of the differences among groups; N/D, not detected; LBW, low birth weight. Mean
metabolite abundance is indicated by arbitrary units of intensity (AUIx10-3).
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glycogen fragments), lipids (spectral region containing large
LDL + VLDL lipoprotein peaks) and phenylalanine was
comparable between the two groups (Table 2, p-value
Control vs LBW). In contrast, the feto-maternal ratio for
proline, free choline, glutamine and alanine was signifi-
cantly lower (p < 0.05) in the LBW group, whereas that for
citrulline was significantly higher.Figure 2 Metabolites distinguishing LBW and control newborns. Gluco
control newborns. Significantly higher levels of citrulline and phenylalanine
metabolite abundance is indicated by line. Each point represents a single nRelationship between metabolites and birth weight
Pearson correlations were performed for each of the 7
aforementioned metabolites versus birth weight. Out of
the 7 metabolites, the analysis identified a significant
positive correlation between birth weight and free
choline, proline, and glutamine (free choline r = 0.50,
p-value <0.01; proline r = 0.29, p-value < 0.05;
glutamine r = 0.36, p-value < 0.01). A significantse, Proline, Glutamine, Choline, and Alanine levels were higher in










































































Figure 3 Spectra of maternal venous plasma. Principal Component Analysis (PCA, panel A) and Projection to Latent Structures for
Discriminant Analysis (PLS-DA, panel B) scores plot for the spectra of maternal venous plasma showing the global metabolic differences between
low birth weight (open circles) and control birth weight (black triangles ) newborns. Apparently, there are no global metabolic trends in the
maternal blood associated with the weight of the newborns.
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birth weight (r = −0.40, p-value <0.01) and between
phenylalanine and birth weight (r = −0.34, p-value
<0.05); i.e., phenylalanine and citrulline increase as
birth weight decreases. No relationships were identi-
fied when correlating these metabolites with blood
pressure. No significant associations were found be-
tween alanine and glucose with birth weight.
Discussion
The present study is the first to utilize metabolomic ana-
lysis in umbilical cord blood samples from LBW chil-
dren in order to identify metabolites that could be
related to the abnormalities associated with the long-
term development of the increased cardio-metabolic risk
associated with LBW. The metabolomic profile of LBW
newborns differed from that observed in a group ofnewborn controls. Higher values of phenylalanine and
citrulline and lower levels of proline, choline, glutamine,
alanine and glucose were observed. A significant rela-
tionship between some of these metabolites and birth
weight was also present. Furthermore, the differences
observed in the newborns were not observed in their
mothers, all of whom were healthy and had similar
weight gains during pregnancy. Although the signifi-
cance of the observed metabolomic values is not well
understood, interesting information can be derived from
the present results since some of the observed data have
been linked previously to the abnormal metabolic states
associated with LBW.
Even though the impact of fetal metabolic program-
ming on adult health is well documented, the underlying
mechanisms are poorly understood. Animal models have
been used extensively to investigate the mechanism by
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alterations in the metabolism of offspring [27-30]. These
studies support the hypothesis that nutritional imbalance
during prenatal and early postnatal life can induce long
term metabolic changes and increase susceptibility to
metabolic diseases in later life [31-33].
The absence of differences found for lipoproteins, car-
bohydrates, ketone bodies and fatty acids suggests that
fatty acid oxidation and glucose metabolism remain un-
altered. Changes, however, in the spectral region be-
tween 7.27 and 5.36 ppm, which has been assigned to
glycogen fragments, may suggest alterations in carbohy-
drate storage. The large molecular size of glycogen
makes it very difficult to observe its 1 H resonance sig-
nals. Longer NMR T2 relaxation times, which suggest
smaller molecule sizes, produce the narrow signals
observed for that spectral region. Perhaps some macro-
molecule degradation of glycogen into smaller molecular
size fragments is the cause.
In the present study, the mismatch between the
mother and the newborn in terms of the metabolomic
profile is worth taking into consideration. While a differ-
ent pattern was observed in the LBW newborns com-
pared to controls, the mothers of both groups had a
similar pattern. A trend towards reduced levels of amino
acids in the umbilical cord was observed in LBW, some-
thing not observed in the mothers. The reason for the
discrepancies is not well known, although suboptimal
placental transport of amino acids could be involved.
Impaired placental amino acid transport is often seen in
association with IUGR, yet it is unclear whether the
changes in amino acid transport are a cause or a conse-
quence of IUGR [34,35]. Experimental models in rats,
however, have suggested a down-regulation of amino
acid transporters as a cause rather than a consequence
[36]. Consistent with impaired placental amino acid
transport as a potential cause of IUGR in humans, um-
bilical cord blood (but not maternal blood) concentra-
tion of most essential amino acids is less in pregnancies
with IUGR fetuses [34], [37]. This interesting finding
should be addressed in future studies.
In contrast to the reduction of the majority of the
amino acid detected are the increased values of phenyl-
alanine, a neutral branched amino acid, in LBW new-
born. Higher levels of amino acids, branched and/or
aromatic, have been associated with insulin resistance
[38,39], and with the risk to develop type 2 diabetes in
the Framingham offspring cohort [19]. The potential for
amino acids to induce insulin resistance has been recog-
nized for some time [40]. In a low-calorie environment,
it is not surprising that large neutral amino acids would
promote an anabolic state by inhibiting proteolysis and
by directly stimulating protein synthesis [41]. That not-
withstanding, the detection of significant spectralregions in the broad protein amide region (between 7.80
and 7.86 ppm) seems to support a potential difference in
the anabolic rate between LBW and control newborns.
One of the greatest differences is the free choline, with
low levels in the LBW group. The spectral region be-
tween 4.06 and 4.08 ppm, belonging to fragments of
phosphoethanolamine [42], also shows statistically sig-
nificant differences in the LBW group. During gestation
there is a high demand for this essential nutrient [43].
Choline, via its metabolite betain, serves as a donor of me-
thyl groups for the production of S-adenosylmethionine
(SAM), a substrate of DNA and histone methyltrans-
ferases [44]. DNA-methylation is catalyzed by DNA
methyltransferases that transfer methyl groups from SAM
to cytosine located in CpG dinucleotides. Different studies
have shown that the prenatal choline supply affects the ex-
pression of multiple genes whose expression is regulated
via epigenetic marks [45], [46]. Maternal choline supply
during pregnancy modifies fetal histone and DNA methy-
lation in rat fetal liver and brain [47]. Conversely, animals
fed with diets deficient in choline and in methionine have
altered global and gene-specific DNA and histone methy-
lation [48]. These studies have demonstrated that mater-
nal choline alterations during pregnancy modify fetal
histone and DNA methylation, suggesting that a concerted
epigenomic mechanism contributes to the long-term de-
velopmental effects of varied choline intake in utero.
Finding that the lower levels of choline are associated
with LBW is compatible with the epigenetic programming
hypothesis. Interactions of nutrients with the epigenetic
machinery lead to changes associated with the regulation
of gene expression that underlies the developmental pro-
gramming consequences in adult life [49]. The epigenetic
programming of the fetus in utero is under the influence
of the altered metabolic milieu of pregnancy and the types
of nutrients available through the maternal diet [50].
Alterations in nutrients, above all those related to DNA
methylation, can modify the levels of DNA methylation
and fetal programming [51]. Disease propensity in LBW
children can be epigenetically programmed by intrauterine
exposures that have the capacity to modify fetal genes
through alterations in DNA methylation [52]. Deregula-
tion of the epigenome may explain changes that are main-
tained throughout adult life. Indeed, lower levels of
choline can explain the link between altered epigenetic
regulation and environmental influence.
The differences found in choline, proline, alanine, glu-
tamine, glucose, citrulline and phenylalanine at birth show
that metabolic alterations are present in LBW. Even
though it will be interesting and useful to clarify the
mechanisms by which these metabolic changes lead to
LBW consequences later in life, they are difficult to estab-
lish at present. Metabolic profile may be useful, however,
in detecting differential phenotypes and in identifying
Ivorra et al. Journal of Translational Medicine 2012, 10:142 Page 9 of 10
http://www.translational-medicine.com/content/10/1/142those populations with the greatest potential risk. The
identification of these differences can facilitate the search
for alterations in tracking studies. These metabolites could
be promising candidates in the search for the molecular
differences capable of explaining the increased risk that
LBW subjects exhibit for developing cardio-metabolic dis-
eases later in life. That notwithstanding, whether or not
these abnormalities are the source of low birth weight is
difficult to establish.
Our findings suggest that a substantial component of
metabolic disease risk has a prenatal developmental
basis. Finding discriminatory metabolites in umbilical
cord blood plasma from LBW newborns with a higher
risk to develop cardio-metabolic disease may lead to
their being used as potential biomarkers for the early
prediction of risk and with the concomitant clinical
implications for follow-up.
Conclusions
Both the presence of the differential metabolic profile, as
well as the relationship of these metabolites with birth
weight demonstrate that metabolic alterations are
present and detectable at birth in LBW subjects. Begin-
ning at birth, metabolic abnormalities provide informa-
tion on the impact of intrauterine life. Whether these
early disturbances in metabolism contribute to the de-
velopment of cardio-metabolic diseases in these subjects
later in life needs to be assessed in prospective studies.
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